TY  - JOUR
A1  - Herrmann, Ken
A1  - Buck, Andreas K.
A1  - Schuster, Tibor
A1  - Abbrederis, Kathrin
A1  - Blümel, Christina
A1  - Santi, Ivan
A1  - Rudelius, Martina
A1  - Wester, Hans-Jürgen
A1  - Peschel, Christian
A1  - Schwaiger, Markus
A1  - Dechow, Tobias
A1  - Keller, Ulrich
T1  - Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
JF  - Oncotarget
N2  - Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.
KW  - [18F]Fluorodeoxythymidine
KW  - FLT-PET
KW  - positron emission tomography
KW  - DLBCL
KW  - lymphoma
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120659
SN  - 1949-2553
VL  - 5
IS  - 12
ER  - 
TY  - JOUR
A1  - Wester, Hans Jürgen
A1  - Keller, Ulrich
A1  - Schottelius, Margret
A1  - Beer, Ambros
A1  - Philipp-Abbrederis, Kathrin
A1  - Hoffmann, Frauke
A1  - Šimeček, Jakub
A1  - Gerngross, Carlos
A1  - Lassmann, Michael
A1  - Herrmann, Ken
A1  - Pellegata, Natalia
A1  - Rudelius, Martina
A1  - Kessler, Horst
A1  - Schwaiger, Markus
T1  - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging
JF  - Theranostics
N2  - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.
KW  - acute myeloid leukemia
KW  - prognostic value
KW  - therapeutic target
KW  - chemokine receptor
KW  - CXCR4
KW  - lymphoma
KW  - in vivo imaging
KW  - positron emission tomography
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144537
VL  - 5
IS  - 6
ER  -